Metin AYTEKİN, Emrah ÇAYLAK

Hiyalüronan, tanı ve tedavideki önemi

İlk olarak 1934’lerde tanımlanan ve hücre dışı matriksinin ana bileşenlerinden glikozaminoglikanların bir alt sınıfı olan hyaluranon, insan vücudunda hem yapısal olarak yer almakta ve hem de fizyolojik olarak birçok fonksiyona katılmaktadır. Özellikle metabolizmasının ve yer aldığı işlevlerde etkisini gösterdiği reseptörlerin daha fazla bilinmesi önem arz etmektedir. Son yıllarda bazı inflamasyon bozuklukları için potansiyel terapötik bir madde olarak değerlendirilen hyaluronanın ayrıca ilişkili olduğu hastalıkların ortaya çıkartılması ve klinik tanıda bazı hastalıklarda bir belirteç (biyomarker) olarak kullanılması ileriki yıllarda onun önemini daha da arttıracaktır. Bu derlememizde hyaluronan molekülünün yapısını ve hastalıklardaki rollerini ele aldık.

Hyaluronan and the importance of hyaluronan in diagnosis and treatment

Hyaluronan is a glycosylaminoglycan and is the main component of the extracellular matrix. It was first described in 1934 and has many structural and physiological functions in the human body. An upcoming area of study relates to the hyaluronan receptors, since these affect the metabolism and function of hyaluronan. This knowledge will be useful in evaluating the role of hyaluronan in diseases, as a therapeutic agent for inflammation disorders and as a diagnostic biomarker. In this review, we discussed the structure of hyaluronan and its role in diseases.

PDF

___

1. Voelcker V, Gebhardt C, Averbeck M, et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008; 17: 100-7.
2. Weigel PH, Frost SJ, LeBoeuf RD, McGary CT. The specific interaction between fibrin (ogen) and hyaluronan: Possible consequences in haemostasis, inflammation and wound healing. Ciba Found Symp 1989; 143: 248-61; discussion 261-4, 281-5.
3. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology 2007; 44: 59-74.
4. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992; 6: 2397-404.
5. Stern R, Maibach HI. Hyaluronan in skin: Aspects of aging and its pharmacologic modulation. Clin Dermatol 2008; 26: 106-22.
6. Gröger M, Niederleithner H, Kerjaschki D, Petzelbauer P. A previously unknown dermal blood vessel phenotype in skin inflammation. J Invest Dermatol 2007; 127: 2893-900.
7. Grskovic B, Pollaschek C, Mueller MM, Stuhlmeier KM. Expression of hyaluronan synthase genes in umbilical cord blood stem/progenitor cells. Biochim Biophys Acta 2006; 1760: 890-5.
8. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: Its nature, distribution, functions and turnover. J Intern Med 1997; 242: 27-33.
9. Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 2000; 156: 529-36.
10. Auvinen PK, Parkkinen JJ, Johansson RT, et al. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer 1997; 74: 477-81.
11. Murray RK, Keeley FW. The extracellular matrix. In: Murray RK, Granner DK, Mayes PA, Rodwell VW (eds). Harper’s Biochemistry. 25th ed. Connecticut, Stamford: Appleton & Lange, 2000: 695-714.
12. Armstrong SE, Bell DR. Measurement of high-molecularweight hyaluronan in solid tissue using agarose gel electrophoresis. Anal Biochem 2002; 308: 255-64.
13. Teder P, Vandivier RW, Jiang D, et al. Resolution of lung inflammation by CD44. Science 2002; 296: 155-8.
14. Mehta S, Stewart DJ, Levy RD. The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 1996; 109: 1550-5.
15. Franzmann EJ, Schroeder GL, Goodwin WJ, et al. Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer 2003; 106: 438-45.
16. Lin K, Bartlett SP, Matsuo K, et al. Hyaluronic acid-filled mammary implants: An experimental study. Plast Reconstr Surg 1994; 94: 306-15; discussion 316-7.
17. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274: 25085-92.
18. Hascall VC, Majors AK, De La Motte CA, et al. Intracellular hyaluronan: A new frontier for inflammation? Biochim Biophys Acta 2004; 1673: 3-12.
19. Aytekin M, Comhair SA, de la Motte C, et al. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: 789-99.
20. de la Motte CA, Hascall VC, Drazba J, et al. Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid: Polycytidylic acid: Inter-alpha-trypsin inhibitor is crucial to structure and function. Am J Pathol 2003; 163: 121-33.
21. Elias JA, Krol RC, Freundlich B, Sampson PM. Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin. J Clin Invest 1988; 81: 325-33.
22. Pienimaki JP, Rilla K, Fulop C, et al. Epidermal growth factor activates hyaluronan synthase 2 in epidermal keratinocytes and increases pericellular and intracellular hyaluronan. J Biol Chem 2001; 276: 20428-35.
23. Stuhlmeier KM, Pollaschek C. Differential effect of transforming growth factor beta (TGF-beta) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-beta-induced hyaluronan synthase 1 activation. J Biol Chem 2004; 279: 8753-60.
24. Li Y, Rahmanian M, Widström C, et al. Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover of HA and induction of types I and III collagen gene expression. Am J Respir Cell Mol Biol 2000; 23: 411-8.
25. Tammi R, Pasonen-Seppänen S, Kolehmainen E, Tammi M. Hyaluronan synthase induction and hyaluronan accumulation in mouse epidermis following skin injury. J Invest Dermatol 2005; 124: 898-905.
26. Yung S, Thomas GJ, Davies M. Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro. Kidney Int 2000; 58: 1953-62.
27. Papakonstantinou E, Kouri FM, Karakiulakis G, et al. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 32: 1504-12.
28. Feusi E, Sun L, Sibalic A, et al. Enhanced hyaluronan synthesis in the MRL-Fas (lpr) kidney: Role of cytokines. Nephron 1999; 83: 66-73.
29. Kreil G. Hyaluronidases-a group of neglected enzymes. Protein Sci 1995; 4: 1666-9.
30. Csoka AB, Frost GI, Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 2001; 20: 499-508.
31. Csoka AB, Scherer SW, Stern R. Expression analysis of six paralogous human hyaluronidase genes clustered on chromosomes 3p21 and 7q31. Genomics 1999; 60: 356-61.
32. Frost GI, Stern R. A microtiter-based assay for hyaluronidase activity not requiring specialized reagents. Anal Biochem 1997; 251: 263-9.
33. Csóka AB, Frost GI, Wong T, Stern R. Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett 1997; 417: 307-10.
34. Rai SK, Duh FM, Vigdorovich V, et al. Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)- anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc Natl Acad Sci USA 2001; 98: 4443-8.
35. Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem 1998; 273: 22466-70.
36. Lathrop WF, Carmichael EP, Myles DG, Primakoff P. cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals. J Cell Biol 1990; 111(6 Pt 2): 2939-49.
37. Cherr GN, Meyers SA, Yudin AI, et al. The PH-20 protein in cynomolgus macaque spermatozoa: Identification of two different forms exhibiting hyaluronidase activity. Dev Biol 1996; 175: 142-53.
38. Stern R, Jedrzejas MJ. Hyaluronidases: Their genomics, structures, and mechanisms of action. Chem Rev 2006; 106: 818-39.
39. Zhang H, Shertok S, Miller K, et al. Sperm dysfunction in the Rb(6.16)- and Rb (6.15)-bearing mice revisited: Involvement of Hyalp1 and Hyal5. Mol Reprod Dev 2005; 72: 404-10.
40. Schnur RE, Herzberg AJ, Spinner N, et al. Variability in the Michelin tire syndrome. A child with multiple anomalies, smooth muscle hamartoma, and familial paracentric inversion of chromosome 7q. J Am Acad Dermatol 1993; 28(2 Pt 2): 364-70.
41. Natowicz MR, Short MP, Wang Y, et al. Clinical and biochemical manifestations of hyaluronidase deficiency. N Engl J Med 1996; 335: 1029-33.
42. Brecht M, Mayer U, Schlosser E, Prehm P. Increased hyaluronate synthesis is required for fibroblast detachment and mitosis. Biochem J 1986; 239: 445-50.
43. Naor D, Nedvetzki S, Walmsley M, et al. CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci 2007; 1110: 233-47.
44. Evanko SP, Angello JC, Wight TN. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1004-13.
45. Deudon E, Berrou E, Breton M, Picard J. Growth-related production of proteoglycans and hyaluronic acid in synchronous arterial smooth muscle cells. Int J Biochem 1992; 24: 465-70.
46. Yang B, Yang BL, Savani RC, Turley EA. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 1994; 13: 286-96.
47. Hardwick C, Hoare K, Owens R, et al. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol 1992; 117: 1343-50.
48. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001; 22: 317-21.
49. Karkkainen MJ, Alitalo K. Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin Cell Dev Biol 2002; 13: 9-18.
50. Bono P, Wasenius VM, Heikkilä P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004; 10: 7144-9.
51. Lesley J, Kincade PW, Hyman R. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol 1993; 23: 1902-9.
52. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: An information-rich system. Eur J Cell Biol 2006; 85: 699-715.
53. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003; 14: 2262-76.
54. Hall CL, Turley EA. Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. J Neurooncol 1995; 26: 221-9.
55. Mohapatra S, Yang X, Wright JA, et al. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 1996; 183: 1663-8.
56. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801.
57. Toole BP, Ghatak S, Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 2008; 9: 249-52.
58. Paulsson M, Heinegard D. Noncollagenous cartilage proteins current status of an emerging research field. Coll Relat Res 1984; 4: 219-29.
59. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest 1996; 98: 2403-13.
60. Hill AT, Bayley DL, Campbell EJ, et al. Airways inflammation in chronic bronchitis: The effects of smoking and alpha1-antitrypsin deficiency. Eur Respir J 2000; 15: 886-90.
61. Maier LA. Clinical approach to chronic beryllium disease and other nonpneumoconiotic interstitial lung diseases. J Thorac Imaging 2002; 17: 273-84.
62. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: Mechanisms of action. Arthritis Res Ther 2003; 5: 54-67.
63. Noble PW, Jiang D. Matrix regulation of lung injury, inflammation, and repair: The role of innate immunity. Proc Am Thorac Soc 2006; 3: 401-4.
64. Rooney P, Kumar S, Ponting J, Wang M. The role of hyaluronan in tumour neovascularization (review). Int J Cancer 1995; 60: 632-6.
65. Reissen R, Wight TN, Pastore C, et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation 1996; 93: 1141-7.
66. Fischer JW, Schror K. Regulation of hyaluronan synthesis by vasodilatory prostaglandins. Implications for atherosclerosis. Thromb Haemost 2007; 98: 287-95.
67. Chen WY, Abatangelo G. Functions of hyaluronan in wound repair. Wound Repair Regen 1999; 7: 79-89.
68. King SR, Hickerson WL, Proctor KG. Beneficial actions of exogenous hyaluronic acid on wound healing. Surgery 1991; 109: 76-84.
69. Balazs EA, Bland PA, Denlinger JL, et al. Matrix engineering. Blood Coagul Fibrinolysis 1991; 2: 173-8.
70. Adina B. The influence of viscoelastic substances on the corneal endothelium during cataract surgery by phacoemulsification. Oftalmologia 2008; 52: 84-9.
71. Balazs EA. Hyaluronan as an ophthalmic viscoelastic device. Curr Pharm Biotechnol 2008; 9: 236-8.
72. Graue EL, Polack FM, Balazs EA. The protective effect of Na-hyaluronate to corneal endothelium. Exp Eye Res 1980; 31: 119-27.
73. Olczyk P, Komosinska-Vassev K, Winsz-Szczotka K, et al. Hyaluronan: Structure, metabolism, functions, and role in wound healing. Postepy Hig Med Dosw (Online) 2008; 62: 651-9.
74. Lydatakis H, Hager IP, Kostadelou E, et al. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006; 26: 864-71.
75. Schiavon LL, Narciso-Schiavon JL, Carvalho Filho RJ, et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008; 15: 666-74.
76. Bolarin DM, Azinge EC. Biochemical markers, extracellular components in liver fibrosis and cirrhosis. Nig Q J Hosp Med 2007; 17: 42-52.
77. Khan JA, Khan FA, Dilawar M, et al. Serum hyaluronic acid as a marker of hepatic fibrosis. J Col Physicians Surg Pak 2007; 17: 323-6.
78. Guechot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-63.
79. Chen HC, Shah S, Stabler TV, et al. Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: The CARRIAGE family study. Osteoarthritis Cartilage 2008; 16: 1054-9.
80. Kato S, Yamada H, Terada N, et al. Joint biomarkers in idiopathic femoral head osteonecrosis: Comparison with hip osteoarthritis. J Rheumatol 2005; 32: 1518-23.
81. Balazs EA, Denlinger JL. Clinical uses of hyaluronan. Ciba Found Symp, 1989; 143: 265-75; discussion 275-80, 281-5.
82. D'Souza M, Datta K. Studies on the affinity of hyaluronic acid binding protein to glycosaminoglycans. Biochem Int 1986; 13: 89-100.
83. Fukuda K, Dan H, Takayama M, et al. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of interleukin-1. J Pharmacol Exp Ther 1996; 277: 1672-5.
84. Asari A, Miyauchi S, Matsuzaka S, et al. Molecular weight- dependent effects of hyaluronate on the arthritic synovium. Arch Histol Cytol 1998; 61: 125-35.
85. Gotoh S, Onaya J, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis 1993; 52: 817-22.
86. Yoshizaki A, Iwata Y, Komura K, et al. Clinical significance of serum hyaluronan levels in systemic sclerosis: Association with disease severity. J Rheumatol 2008; 35: 1825-9.
87. Freitas JP, Filipe P, Emerit I, et al. Hyaluronic acid in progressive systemic sclerosis. Dermatology 1996; 192: 46-9.
88. Herman MP, Svatek RS, Lotan Y, et al. Urine-based biomarkers for the early detection and surveillance of nonmuscle invasive bladder cancer. Minerva Urol Nefrol 2008; 60: 217-35.
89. Kosaki R, Watanabe K, Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999; 59: 1141-5.
90. Guo Y, Ma J, Wang J, et al. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 1994; 54: 1561-5.
91. Rahmanian M, Pertoft H, Kanda S, et al. Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro. Exp Cell Res 1997; 237: 223-30.
92. Montesano R, Kumar S, Orci L, Pepper MS. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest 1996; 75: 249-62.
93. Itano N, Sawai T, Atsumi F, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 2004; 279: 18679-87.
94. Engström-Laurent A, Laurent UB, Lilja K, Laurent TC. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest 1985; 45: 497-504.
95. Lindqvist U, Laurent TC. Serum hyaluronan and aminoterminal propeptide of type III procollagen: Variation with age. Scand J Clin Lab Invest 1992; 52: 613-21.